The manufacturer’s data show that the immune system of people vaccinated with its Janssen vaccine has been resistant to the virus for at least eight months.
–
“Current data from the eight months examined so far show that the single-dose J&J vaccine produces a strong antibody response that does not weaken; on the contrary, we are seeing an improvement over time, ”said Mathai Mammen, Head of Research and Development at J&J Pharmaceuticals.
–
The vaccine elicits higher activity of antibodies against the Indian variant of delta than against the dangerous South African mutation, now known as beta, the company said. The South African mutation can partially bypass the body’s immune response.
–
Data that did not pass the peer review procedure was published by J&J on the bioRxiv professional website.
–
The Johnson & Johnson vaccine was considered very promising because one dose is enough. However, as with other adenovirus vaccines, rare cases of thrombosis have been reported and its use in younger people is not recommended. In the EU, they want to focus mainly on the administration of mRNA vaccines, such as those produced by Moderna and Pfizer / BioNTech.
–
